Overview

Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

Sunil Agarwal Joins Juno Therapeutics as President of Research and Development

Sunil-headshotWith Dr. Agarwal’s appointment, Juno will bring Research and Development under one leader responsible for the execution of Juno’s drug development pipeline, integration of translational insights into ongoing programs, and the prioritization of research and development initiatives. Prior to joining Juno, Dr. Agarwal’s last industry role was Chief Medical Officer, Executive Vice President at Ultragenyx.

read more

Corsee D. Sanders Appointed Executive Vice President and Head of Development Operations at Juno Therapeutics

AubreyHord_CSanders_003-2Corsee D. Sanders, Ph.D. will be responsible for the planning, management, execution, analysis, and reporting of Juno’s clinical trials. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals.

read more

Our Science

The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno’s technologies genetically engineer a patient’s own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. We use two different technologies to target cancer cells and activate T cells, CARs and TCRs.

Juno Spotlights

Juno’s Media Page

Media Link

Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptor (CAR) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins.

T Cell Receptors (TCRs)

High-affinity TCR technology provides T cells with a specific T cell receptor that recognizes cancer cells based on expression of specific proteins inside the cell or on the cell surface.

For Patients

For more information about our investigational clinical trials, please visit our Pipeline page.